Display options
Cite
Petrizzo A, Mauriello A, Tornesello ML, et al. Cellular prognostic markers in hepatitis-related hepatocellular carcinoma. Infect Agent Cancer. 2018;13:10doi: 10.1186/s13027-018-0183-8.
Petrizzo, A., Mauriello, A., Tornesello, M. L., Buonaguro, F. M., Tagliamonte, M., & Buonaguro, L. (2018). Cellular prognostic markers in hepatitis-related hepatocellular carcinoma. Infectious agents and cancer, 1310. https://doi.org/10.1186/s13027-018-0183-8
Petrizzo, A, et al. "Cellular prognostic markers in hepatitis-related hepatocellular carcinoma." Infectious agents and cancer vol. 13 (2018): 10. doi: https://doi.org/10.1186/s13027-018-0183-8
Petrizzo A, Mauriello A, Tornesello ML, Buonaguro FM, Tagliamonte M, Buonaguro L. Cellular prognostic markers in hepatitis-related hepatocellular carcinoma. Infect Agent Cancer. 2018 Mar 27;13:10. doi: 10.1186/s13027-018-0183-8. eCollection 2018. PMID: 29599818; PMCID: PMC5870199.
Copy Download .nbib Format: NLM
Share it on

Infect Agent Cancer. 2018 Mar 27;13:10. doi: 10.1186/s13027-018-0183-8. eCollection 2018.

Cellular prognostic markers in hepatitis-related hepatocellular carcinoma.

Infectious agents and cancer

A Petrizzo, A Mauriello, M L Tornesello, F M Buonaguro, M Tagliamonte, L Buonaguro

Affiliations

  1. 1Laboratory of Cancer Immunoregulation, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale" - IRCCS, Via Mariano Semmola, 1, 80131 Naples, Italy.
  2. 2Lab Molecular Biology and Viral Oncology, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale" - IRCCS, Via Mariano Semmola, 1, 80131 Naples, Italy.

PMID: 29599818 PMCID: PMC5870199 DOI: 10.1186/s13027-018-0183-8

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and accounts for about 6% of all new cancers diagnosed worldwide. Moreover, it is the third and the fifth leading cause of death from cancer in men and women, respectively. HBV and HCV chronic infection is the main risk factor for HCC. A range of therapies are used in the management of HCC according to the extent and severity of liver disease. In this perspective, evaluation of prognosis represents a crucial step for proper management of HCC patients. However, the clinical outcome can be significantly different in HCC patients within the same stage of disease. Therefore, many efforts have been made to define new parameters with more precise prognostic value, and the search for HCC prognostic markers is gaining momentum. The present review aims at providing an update on cellular prognostic markers for HCC.

Keywords: Cellular prognostic markers; Hepatocellular carcinoma; Immunoscore

Conflict of interest statement

Not Applicable.Not Applicable.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affilia

References

  1. Future Oncol. 2015;11(11):1591-8 - PubMed
  2. Clin Exp Immunol. 2013 Jan;171(1):36-45 - PubMed
  3. Sci Rep. 2017 Aug 8;7(1):7525 - PubMed
  4. World J Gastroenterol. 2014 Jun 28;20(24):7971-8 - PubMed
  5. J Clin Oncol. 2007 Jun 20;25(18):2586-93 - PubMed
  6. J Clin Oncol. 2008 Jun 1;26(16):2707-16 - PubMed
  7. Clin Cancer Res. 2007 Feb 1;13(3):902-11 - PubMed
  8. PLoS One. 2012;7(1):e30806 - PubMed
  9. Cancer Lett. 2012 May 28;318(2):154-61 - PubMed
  10. J Pathol. 2014 Jan;232(2):199-209 - PubMed
  11. Cancer Cell. 2010 Feb 17;17(2):135-47 - PubMed
  12. Oncotarget. 2015 Nov 3;6(34):35602-15 - PubMed
  13. Cancer Immunol Res. 2016 May;4(5):419-30 - PubMed
  14. Science. 2006 Sep 29;313(5795):1960-4 - PubMed
  15. Clin Cancer Res. 2014 Apr 1;20(7):1891-9 - PubMed
  16. PLoS One. 2013 May 07;8(5):e63243 - PubMed
  17. Cancer. 2014 Sep 15;120(18):2824-38 - PubMed
  18. N Engl J Med. 2006 Sep 21;355(12):1253-61 - PubMed
  19. J Innate Immun. 2014;6(6):716-26 - PubMed
  20. Gut. 2010 Jul;59(7):953-62 - PubMed
  21. J Hepatol. 2011 Mar;54(3):497-505 - PubMed
  22. HPB (Oxford). 2013 Jun;15(6):439-48 - PubMed
  23. Gene Expr. 2014;16(2):77-84 - PubMed
  24. Cancer Prev Res (Phila). 2013 Jun;6(6):594-602 - PubMed
  25. Int J Oncol. 2012 Jun;40(6):1733-47 - PubMed
  26. J Clin Oncol. 2009 Oct 1;27(28):4709-17 - PubMed
  27. Cell. 2006 Jan 27;124(2):263-6 - PubMed
  28. Physiol Rev. 2008 Jan;88(1):125-72 - PubMed
  29. J Hepatol. 2012 Apr;56(4):908-43 - PubMed
  30. Curr Opin Genet Dev. 2009 Feb;19(1):67-73 - PubMed
  31. Annu Rev Pathol. 2011;6:425-56 - PubMed

Publication Types